ybiologics Venture Capital
3 known investors
Y-Biologics (와이바이오로직스) develops antibody-based drugs using its antibody discovery, fully human antibody library, and antibody engineering technologies, working through its own pipeline and partner collaborations. Its programs include next-generation immuno-oncology therapies such as Multi-AbKine, a multi antibody-cytokine fusion aimed at cancers resistant to existing immunotherapies, along with bispecific antibodies, VHH nanobodies, pH-sensitive antibodies, and ADC antibodies.
Investors · 3
Frequently asked questions
- What does ybiologics Venture Capital do?
- Y-Biologics (와이바이오로직스) develops antibody-based drugs using its antibody discovery, fully human antibody library, and antibody engineering technologies, working through its own pipeline and partner collaborations. Its programs include next-generation immuno-oncology therapies such as Multi-AbKine, a multi antibody-cytokine fusion aimed at cancers resistant to existing immunotherapies, along with bispecific antibodies, VHH nanobodies, pH-sensitive antibodies, and ADC antibodies.
- Who are ybiologics Venture Capital's investors?
- ybiologics Venture Capital's investors include Aju IB Invesment Corporation, IMM Investment Japan, Kiwoom Investment.